Hall Ashley 4
4 · Reneo Pharmaceuticals, Inc. · Filed Aug 29, 2023
Insider Transaction Report
Form 4
Hall Ashley
Chief Development Officer
Transactions
- Exercise/Conversion
Common Stock
2023-08-28$1.80/sh+15,625$28,125→ 55,225 total - Exercise/Conversion
Stock option (right to buy)
2023-08-28−15,625→ 109,375 totalExercise: $1.80Exp: 2032-12-08→ Common Stock (15,625 underlying) - Sale
Common Stock
2023-08-28$6.28/sh−15,625$98,058→ 39,600 total
Footnotes (3)
- [F1]Includes 4,000 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan (the "Plan") on June 8, 2023.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.24 to $6.44, inclusive. The reporting person undertakes to provide any security holder of Reneo Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
- [F3]The shares vest in a series of 16 equal quarterly installments measured from December 9, 2022 subject to Reporting Person's Continuous Service (as defined in the Issuer's 2021 Equity Incentive Plan) as of each such vesting date.